中偉股份(300919.SZ):擬向IFC申請授信不超1.5億美元貸款及子公司提供擔保
格隆匯12月9日丨中偉股份(300919.SZ)公佈,公司於2021年12月9日召開第一屆董事會第二十四次會議,審議通過《關於向金融機構申請授信貸款及子公司為公司提供擔保的議案》,同意公司向國際金融公司(INTERNATIONAL FINANCE CORPORATION,“IFC”)申請授信總額不超過1.5億美元(或等值人民幣)的貸款並由公司和其子公司貴州中偉資源循環產業發展有限公司(“貴州中偉循環”)、湖南中偉新能源科技有限公司(“湖南中偉新能源”)、廣西中偉新能源科技有限公司(“廣西中偉新能源”)為此次貸款提供擔保。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.